Floatz logo

Autologous Bcma/Gprc5D Dual-Target Car-T

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL

Beijing BiotechCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

316 Active assets in the Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

Autologous Bcma/Gprc5D Dual-Target Car-T is also rated in:

B-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
47 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
47 / 100
View asset →
Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →